Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CDNA 
CareDx Inc (CDNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: CDNA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $22.2
1 Year Target Price $22.2
| 4 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -52.27% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 629.14M USD | Price to earnings Ratio 11.26 | 1Y Target Price 22.2 |
Price to earnings Ratio 11.26 | 1Y Target Price 22.2 | ||
Volume (30-day avg) 8 | Beta 2.22 | 52 Weeks Range 10.96 - 34.84 | Updated Date 08/15/2025 |
52 Weeks Range 10.96 - 34.84 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.1 | Actual 0.1 |
Profitability
Profit Margin 17.06% | Operating Margin (TTM) -12.43% |
Management Effectiveness
Return on Assets (TTM) -5.85% | Return on Equity (TTM) 19.64% |
Valuation
Trailing PE 11.26 | Forward PE - | Enterprise Value 472009525 | Price to Sales(TTM) 1.85 |
Enterprise Value 472009525 | Price to Sales(TTM) 1.85 | ||
Enterprise Value to Revenue 1.38 | Enterprise Value to EBITDA -2.82 | Shares Outstanding 53226900 | Shares Floating 51881903 |
Shares Outstanding 53226900 | Shares Floating 51881903 | ||
Percent Insiders 3.43 | Percent Institutions 103.86 |
Upturn AI SWOT
CareDx Inc
Company Overview
History and Background
CareDx, Inc. was founded in 1998. The company focuses on developing and commercializing solutions for transplant patients and care providers. CareDx has grown through internal development and strategic acquisitions, expanding its offerings in transplant monitoring.
Core Business Areas
- Transplant Monitoring Solutions: CareDx offers a range of diagnostic tests and services used to monitor the health of transplant recipients. These solutions help clinicians detect early signs of rejection and optimize immunosuppressant therapy.
Leadership and Structure
CareDx has a board of directors overseeing the executive leadership team. The leadership team is responsible for setting the company's strategic direction and managing its operations.
Top Products and Market Share
Key Offerings
- AlloSure: AlloSure is a donor-derived cell-free DNA (dd-cfDNA) test used to monitor kidney transplant recipients for rejection. CareDx states it is the leading non-invasive test used for kidney transplant surveillance with the largest body of clinical evidence. Competitors include Natera (NTRA) with Prospera.
- AlloMap: AlloMap Heart is a gene expression profiling test used to monitor heart transplant recipients. Allows clinicians to determine risk of organ rejection in heart transplant patients. Competitors include Abbott (ABT) with Corus CAD and Thermo Fisher Scientific (TMO) with QTrace.
Market Dynamics
Industry Overview
The transplant diagnostics market is growing, driven by increasing transplant volumes and the need for non-invasive monitoring solutions. The market is characterized by technological innovation and increasing regulatory scrutiny.
Positioning
CareDx is a leading provider of transplant monitoring solutions. Its competitive advantages include its established market presence, proprietary technology, and strong relationships with transplant centers. The company continues to innovate and expand its product portfolio to meet the evolving needs of transplant patients.
Total Addressable Market (TAM)
The estimated TAM for transplant diagnostics and monitoring is several billion dollars. CareDx is well-positioned to capture a significant share of this market with its comprehensive portfolio of products and services.
Upturn SWOT Analysis
Strengths
- Established Market Position
- Proprietary Technology
- Strong Relationships with Transplant Centers
- Comprehensive Product Portfolio
- First Mover Advantage
Weaknesses
- Reliance on Reimbursement Policies
- Competition from Larger Diagnostic Companies
- Relatively High Cost of Testing
- Past Allegations and Lawsuits
Opportunities
- Expanding Product Portfolio to Include Other Organ Transplants
- Developing New Biomarkers for Rejection
- Increasing Adoption of Non-Invasive Monitoring Solutions
- Geographic Expansion
Threats
- Changes in Reimbursement Policies
- Increased Competition
- Technological Disruption
- Economic Downturn
Competitors and Market Share
Key Competitors
- Natera (NTRA)
- Thermo Fisher Scientific (TMO)
- Abbott (ABT)
Competitive Landscape
CareDx's advantages include its strong brand recognition and established market presence. However, it faces competition from larger diagnostic companies with more resources and broader product portfolios.
Major Acquisitions
Transplant Genomics
- Year: 2019
- Acquisition Price (USD millions): 75
- Strategic Rationale: Expanded CareDx's portfolio of transplant diagnostic solutions by adding a proprietary gene expression test for kidney transplant rejection.
Growth Trajectory and Initiatives
Historical Growth: CareDx has experienced significant revenue growth driven by the increasing adoption of its transplant monitoring solutions. Growth rates have varied depending on market conditions and competitive pressures.
Future Projections: Future growth is projected to be driven by expanding product portfolio, increasing adoption of non-invasive monitoring, and geographic expansion. Analyst estimates will vary based on different forecasts.
Recent Initiatives: Recent strategic initiatives include developing new tests for different organ transplants, expanding into new markets, and forming partnerships with leading transplant centers.
Summary
CareDx is a leading player in the transplant diagnostics market, with a strong position in non-invasive monitoring solutions. Its growth is driven by increasing transplant volumes and the need for better monitoring tools. However, the company faces challenges from larger competitors and changes in reimbursement policies. Successful execution of its expansion strategies will be crucial for its future performance.
Peer Comparison
Sources and Disclaimers
Data Sources:
- CareDx Inc. SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CareDx Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2014-07-17 | President, CEO & Director Mr. John Walter Hanna Jr. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 644 | Website https://caredx.com |
Full time employees 644 | Website https://caredx.com | ||
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI, a transplant quality tracking software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.